Treating allergic rhinitis in pregnancy

Curr Allergy Asthma Rep. 2006 May;6(3):232-8. doi: 10.1007/s11882-006-0040-5.

Abstract

Numerous pregnant women suffer from allergic rhinitis, and particular attention is required when prescribing drugs to these patients. In addition, physiologic changes associated with pregnancy could affect the upper airways. Evidence-based guidelines on the management of allergic rhinitis have been published. Medication can be prescribed during pregnancy when the apparent benefit of the drug is greater than the apparent risk. Usually, there is at least one "safe" drug from each major class used to control symptoms. All glucocorticosteroids are teratogenic in animals but, when the indication is clear (for diseases possibly associated, such as severe asthma exacerbation), the benefit of the drug is far greater than the risk. Inhaled glucocorticosteroids (eg, beclomethasone or budesonide) have not been incriminated as teratogens in humans and are used by pregnant women who have asthma. A few H1-antihistamines can safely be used as well. Most oral decongestants (except pseudoephedrine) are teratogenic in animals. There are no such data available for intranasal decongestants. Finally, pregnancy is not considered to be a contraindication for the continuation of immunotherapy.

Publication types

  • Retracted Publication
  • Review

MeSH terms

  • Animals
  • Cholinergic Antagonists / therapeutic use
  • Chromones / therapeutic use
  • Desensitization, Immunologic
  • Female
  • Glucocorticoids / therapeutic use
  • Histamine H1 Antagonists / therapeutic use
  • Humans
  • Nasal Decongestants / therapeutic use
  • Pregnancy*
  • Rhinitis, Allergic, Perennial / drug therapy*
  • Rhinitis, Allergic, Seasonal / drug therapy*
  • Teratogens

Substances

  • Cholinergic Antagonists
  • Chromones
  • Glucocorticoids
  • Histamine H1 Antagonists
  • Nasal Decongestants
  • Teratogens